CENCORA, INC. Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount
CENCORA, INC. (COR) reported Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount of $113.50 million for the 12-month period ending 2025-09-30, per its 8-K filed 2026-02-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount · last filed 2026-02-10
| Period end | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month |
|---|---|
| 2025-09-30 | $113.50M 8-K · filed 2026-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CARDINAL HEALTH INC (CAH) | United States | $51.753B | 29.38 |
| MCKESSON CORP (MCK) | United States | $101.317B | 19.78 |
| HERBALIFE LTD. (HLF) | $1.281B | 8.39 | |
| NU SKIN ENTERPRISES, INC. (NUS) | United States | $0.225B | -1.18 |
| Cosmos Health Inc. (COSM) | Greece | $0.038B | -0.60 |
| HWH International Inc. (HWH) | United States | $0.021B | -4.08 |
| DataMeds AI, Inc. (MEDS) | United States | $0.011B |